Invitrogen will invest in Blue Heron in exchange for worldwide rights to distribute Blue Heron's custom gene synthesis services.
Under the terms of the agreement, Invitrogen will become the exclusive worldwide distributor of Blue Heron's synthetic genes. The financial terms of the agreement were not disclosed.
Blue Heron Biotechnology's proprietary GeneMaker® platform is designed to synthesize any gene sequence regardless of length or complexity. Researchers worldwide are increasingly turning to synthetic genes as an alternative for traditional cloning.
Synthetic genes has allowed pharmaceutical and biotechnology companies to speed the drug discovery process through an ability to synthesize known genes, and produce from them novel proteins, new vaccines and diagnostics.
"Invitrogen recognizes the tremendous new possibilities that gene synthesis offers life science researchers," said Nathan Wood, Vice President of Cloning and Protein Expression.
"We have developed a broad array of products that complement Blue Heron's GeneMaker® platform and this agreement continues to enhance our portfolio offerings to our customers."
"Partnering with a life sciences leader such as Invitrogen is an important milestone in Blue Heron Bio's continued growth and signals an important milestone for the overall gene synthesis market as well. We are very pleased to be able to make our gene synthesis services available through Invitrogen's unmatched distribution and marketing channels," said John Fess, CEO of Blue Heron Biotechnology.
As part of the agreement, the companies will co-develop new products and services for the research and bio-pharmaceutical markets.